Renal anemia is a common complication of chronic kidney disease (CKD). Although treatments—such as iron therapies, erythropoiesis-stimulating agents (ESAs), and HIF-PH inhibitors—are available…
The rising rates of antimicrobial resistance (AMR) have created an emergent need for development and discovery of antibiotics with activity against drug-resistant gram-negative pathogens (GNPs)…
Attention-deficit/hyperactivity disorder (ADHD) is one of most common pediatric disorders and one that can continue into adulthood. For decades, pediatric ADHD has been treated primarily with…
Treatment of psoriatic arthritis (PsA) typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S…
Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum. Treatment typically begins with conventional agents (e.g., 5-aminosalicylic acids [5-ASAs])…
The ovarian cancer treatment landscape has been transformed by the angiogenesis inhibitor bevacizumab and the poly ADP ribose polymerase (PARP) inhibitors Lynparza (AstraZeneca / Merck & Co.),…
The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics / targeted oral therapies and grow steadily over the next 10 years. The well-established TNF-α inhibitors (…
Myasthenia gravis (MG) is a rare neuromuscular disorder caused by specific autoantibodies at the neuromuscular junction targeting—in most patients—acetylcholine receptors. It is characterized…
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder that leads to a decline in platelet production, thus increasing the risk of bleeding. Current therapies for ITP can be broadly…
Multiple guidelines recommend treating post-traumatic stress disorder (PTSD) first with psychotherapy. However, such approaches do not suffice for many patients, necessitating the use of…
The hepatocellular carcinoma therapy market is gradually evolving and experiencing substantial growth. While angiogenesis inhibitors, including sorafenib (Bayer / Amgen), Stivarga (Bayer), Lenvima…
Immunoglobulin A nephropathy (IgAN or IgA nephropathy), also known as Berger’s disease, is a rare autoimmune condition that damages the glomeruli inside the kidneys. Initial treatment of IgAN…
Acute coronary syndrome (ACS)—subtype of coronary artery disease (CAD)—is an umbrella term encompassing ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable…
Dry eye disease (DED) is a condition characterized by the loss of tear film homeostasis, caused by the inadequate production or the rapid evaporation of tears. For 13 years, AbbVie’s Restasis was…
Eisai / Biogen’s Leqembi (lecanemab) gained accelerated and full FDA approval in 2023 based on positive clinical and biomarker outcomes from the Phase 3 CLARITY-AD trial. With the U.S. CMS…